Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging

Shanghai Mental Health Center1 site in 1 country300 target enrollmentNovember 2019

ConditionsMild Cognitive Impairment Biomarker Diagnosis Treatment

InterventionsPlacebo Huperzine A

DrugsHuperzine A Placebo

Overview

Phase: Phase 4
Intervention: Placebo
Conditions: Mild Cognitive Impairment
Sponsor: Shanghai Mental Health Center
Enrollment: 300
Locations: 1
Primary Endpoint: The average annual conversion rate in patients of MCI due to AD convert to the AD.
Status: Not yet recruiting
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is based on the Flutemetamol-PET senile plaque imaging to investigate the peripheral blood biochemical and brain MRI imaging biomarkers and to research completely independent intellectual property rights neuropsychological test tool for the MCI due to AD. At the same time, the investigators will study the efficacy and safety of early treatment of MCI due to AD by Huperzine A in 52 weeks.

Detailed Description

This is a randmized, double-blind, placebo-controll study.

Registry

clinicaltrials.gov

Start Date

November 2019

End Date

December 2025

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Shanghai Mental Health Center

Responsible Party

Principal Investigator

xiaoshifu

Director

Shanghai Mental Health Center

Eligibility Criteria

Inclusion Criteria

•memory complaint, preferably corroborated by a spouse or relative.
•objective memory impairment.
•normal general cognitive function.
•intact activities of daily living.
•absence of dementia.
•the positive of brain senile plaque.

Exclusion Criteria

•more than two lacuna ischemia (of diameter \< 1 cm) as revealed by MRI fluid-attenuated inversion recovery (FLAIR) sequence.
•other type of dementia except AD